IMRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Immuneering commented on the FDA's approval in second-line metastatic pancreatic cancer and reiterated its focus on first-line patientsAug 27, 2026
- Immuneering dosed the first patient in the pivotal Phase 3 MAPKeeper 301 trial for pancreatic cancerJun 11, 2026
- Immuneering reports median overall survival of 17.3 months in metastatic pancreatic cancer studyMay 23, 2026
- Immuneering will present new survival data for first-line pancreatic cancer patients treated with Atebimetinib plus mGnPApr 22, 2026
- Immuneering announces extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with Atebimetinib + mGnPSep 25, 2025